Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL1102 in non-ambulatory Duchenne muscular dystrophy
2022-003065-38Phase 2Terminated
- Sponsor
- Percheron Therapeutics Ltd
- Start
- Dec 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avicursen in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Percheron Therapeutics Ltd. Primary endpoint: Change in Performance of Upper Limb 2.0 score. Started Dec 2022; status: terminated.
02
Drugs
avicursen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2022-003065-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003065-38.